Bristol Myers Squibb Presents First Clinical Data from Two Phase 3 Studies in the ADEPT Program Evaluating KarXT for Psychosis Associated with Alzheimer’s Disease
Wednesday, November 18, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: Bristol Myers Squibb presented initial clinical data from two Phase 3 studies in the ADEPT program. The studies evaluate KarXT for treating psychosis associated with Alzheimer's disease. This marks a significant step in exploring new treatment options for patients suffering from this condition.
Market Sentiment Analysis
POSITIVE FACTORS
First clinical data presented from Phase 3 studies
Focus on KarXT for Alzheimer's-related psychosis
Potential advancement in Alzheimer's treatment
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+19%
120-day peak, hindsight
Typical move
1.7%
average across 15 past catalysts
Lead asset
Mezigdomide
NDA/BLA · Relapsed or Refractory Multiple Myeloma
Full Press Release Details
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ADEPT--BMS Presents First Clinical Data from Two Phase 3 Studies in the ADEPT Program Evaluating KarXT for Psychosis Associated with Alzheimer’s Disease
Frequently Asked Questions
What is the ADEPT program?
The ADEPT program evaluates KarXT for psychosis associated with Alzheimer's disease.
What did BMS present?
BMS presented initial clinical data from two Phase 3 studies.
What is KarXT used for?
KarXT is being evaluated for treating psychosis in Alzheimer's patients.